Skip to main content

Day: September 22, 2021

Workhorse Group Provides Update on Review of Operating and Commercialization Plans

Remains on Track to Provide Long Term Strategic Roadmap on Q3 Earnings Call CINCINNATI, Sept. 22, 2021 (GLOBE NEWSWIRE) — Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on providing sustainable and cost-effective drone-integrated electric vehicles to the last-mile delivery sector, today provided an update to its ongoing review of the Company’s business and go-forward operating and commercial plans to transition from an advanced technology start-up to an efficient manufacturing company. The Company has identified a number of enhancements in the production process and design of the C-1000 to address customer feedback, primarily related to vehicle dynamics to increase the vehicles’ payload capacity. As Workhorse has identified these enhancements and continued its review and...

Continue reading

CEO Doubles Down Purchasing Large Block of Restricted Common Stock, Debt, and Preferred Stock in Private Transaction Aimed to Strengthen the Capital Structure

Powder Springs, GA, Sept. 22, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — CBMJ CEO Mark Schaftlein, through his company Capital Consulting Inc., has purchased an additional 31M shares of Restricted Common Stock, $30,000 of Convertible Debt with a current balance of $57,775 in a Private Purchase transaction, and 25% interest in Preferred Stock.  With the addition of the 31M shares, Capital Consulting Inc. now owns a total of 60,913,500 restricted Common Shares, which represents 17% of the total Issued and Outstanding Common shares. This more than doubles the shares controlled by the Company’s CEO.  “Closing this transaction further solidifies continued commitment my fellow Directors and I have to building shareholder value for the long term. Coupled with the recent warrant exercise by Capital Consulting Inc., and an investment...

Continue reading

Healthy Extracts Begins New Clinical Trial to Investigate Ability of UBN RELIEF™ to Naturally Alleviate Migraine Symptoms and Improve Cognitive Function

UBN RELIEF™UBN RELIEF™ is clinically proven to provide some relief from symptoms often related to migraine headaches.LAS VEGAS, Sept. 22, 2021 (GLOBE NEWSWIRE) — Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, has begun a new double-blind placebo-controlled clinical trial designed to further investigate the ability of UBN RELIEF™ to naturally prevent or alleviate symptoms associated with migraines while improving cognitive function. Neil Wolkodoff, PhD, medical program director of the Colorado Center for Health and Sports Science, will administer the trial, which is anticipated to be completed in November. “We believe our clinical research differentiates our products in the marketplace and assures our customers they are buying a product...

Continue reading

SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years

BREXAFEMME® (ibrexafungerp tablets)Product Image #1BREXAFEMME® (ibrexafungerp tablets)Package Image #2BREXAFEMME® (ibrexafungerp tablets)Product LogoSCYNEXIS LogoSCYNEXIS Company LogoFirst and only oral non-azole treatment option approved for vaginal yeast infections is now available in pharmacies including cloud-based pharmacy New treatment is fungicidal against Candida species, disrupting the fungal cell wall and killing the fungi causing the infection, rather than only inhibiting its growthJERSEY CITY, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced the U.S. availability of BREXAFEMME®...

Continue reading

Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

WALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat hosted by Jennifer Kim, Vice President, Equity Research, at the 2021 Cantor Virtual Global Healthcare Conference, taking place on Monday, September 27, 2021, at 9:20 a.m. ET. Checkpoint management will also participate in one-on-one meetings during the conference. A live webcast of the fireside chat will be available on the Events page, located within the Investors section of Checkpoint’s website, https://ir.checkpointtx.com/event-calendar/default.aspx, for approximately 30 days following the meeting. About Checkpoint TherapeuticsCheckpoint Therapeutics,...

Continue reading

Dominion Water Reserves Esker Development

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. MONTREAL, Sept. 22, 2021 (GLOBE NEWSWIRE) — Dominion Water Reserves Corp. (“DWR” or the “Company”) (CSE: DWR), is pleased to announce an investment of $250,000 toward the development of its esker water reserve. As part of its growth strategy and to accelerate its development, DWR will upgrade its installations to facilitate access to bulk transport markets. DWR’s 204 – acre water reserve in the Outaouais region has an authorized annual extraction volume of nearly 1 billion litres, making it the second esker with bottling permit in Quebec with 9.5% of the volume of Quebec’s collection authorizations.    Considering the high quality and available volume of this esker water, DWR is currently in discussion with potential partners, specializing...

Continue reading

PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that its management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference.  The presentation will provide an update on the three ongoing PDS0101 Phase 2 clinical trials. The talk will also provide updates on progression of two other investigational pipeline products PDS0102 (Versamune®-TARP) and PDS0103 (Versamune®-MUC1) into human clinical trials.  The conference is taking place virtually from September 27 – 30, 2021. Details for the presentation are as follows: Cantor Fitzgerald Virtual Global Healthcare Conference:Date: Tuesday, September...

Continue reading

Patriot Glass Solutions, a Division of C-Bond Systems, Names its First Three Distributors to its Network of Security and Ballistic-Resistant Window Film Providers

C-Bond’s Ballistic-Resistant Film System, Validated to Provide NIJ Level I, Level II, and Level IIA Protection, Addresses the Growing Need for Security Film Due to an Increase in Looting, Rioting, and Shootings HOUSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) — C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, today announced its Patriot Glass Solutions division has added three new distributors to its network of security and ballistic-resistant window film providers. The well-established distributors are geographically diverse, located in certain markets in Colorado, California, Michigan, Texas, Utah, Kansas, and Missouri. Patriot Glass Solutions protects personal, commercial and government property from looting, rioting, break-ins, and gunfire. Its leading products are C-Bond BRS, a ballistic-resistant...

Continue reading

Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress

Currently opening sites for Phase III study of nomacopan in bullous pemphigoid (BP).Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) open for enrollment.Evaluating the potential for long-acting PAS-nomacopan as a treatment for dry age-related macular degeneration (AMD).Collaborating with clinical partners to explore potential for treating exacerbations in severe lung diseases where inhaled nomacopan can be potentially delivered directly to the lung.Active pipeline exploring treatment of head trauma with nomacopan and the development of votucalis, a new anti-histamine biopharmaceutical with a similar structure to nomacopan.NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical...

Continue reading

3PL Market worth USD 1,993.72 billion by 2028, registering a CAGR of 8.7% – Report by Market Research Future (MRFR)

New York, Sept. 22, 2021 (GLOBE NEWSWIRE) — 3PL Market Overview: According to a comprehensive research report by Market Research Future (MRFR), “3PL Market Research Report, Service, Mode of Transport, Application and Region – Forecast till 2028” the market is projected to be worth USD 1,993.72 billion by 2028, registering a CAGR of 8.7% during the forecast period (2021 – 2028), The market was valued at USD 921.49 billion in 2020. Key Players Notable players profiled in the global third-party logistics market report areC.H. Robinson Worldwide (US) BDP International Inc. (US) CEVA Logistics (Switzerland) FedEx Corporation (US) DSV Panalpina A/S (Denmark) Burris Logistics (US) DB Schenker Logistics (Germany) DHL International GmbH (Germany) Nippon Express (Japan) Kerry Logistics (Hong Kong). Get Free Sample PDF Brochure https://www.marketresearchfuture.com/sample_request/9996...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.